CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

Clinical Trial ID NCT00659425

Rank	Title	Journal	Year	PubWeight™‹?›
1	A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.	FEBS J	2011	1.70
2	The development of immunoconjugates for targeted cancer therapy.	Nat Rev Clin Oncol	2014	1.49
3	Immunotoxins for leukemia.	Blood	2014	1.33
4	Immunotherapy targets in pediatric cancer.	Front Oncol	2012	0.97
5	Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.	Proc Natl Acad Sci U S A	2012	0.96
6	A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.	J Biol Chem	2013	0.89
7	Novel agents for the treatment of childhood acute leukemia.	Ther Adv Hematol	2015	0.87
8	Immunotherapy for pediatric leukemia.	Front Oncol	2013	0.84
9	Linked-in: design and efficacy of antibody drug conjugates in oncology.	Oncotarget	2013	0.82
10	The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.	MAbs	2011	0.80
11	Immune-based therapeutics for pediatric cancer.	Expert Opin Biol Ther	2010	0.78
12	Immunotherapy in pediatric malignancies: current status and future perspectives.	Future Oncol	2014	0.78
13	Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives.	Front Oncol	2013	0.77
14	Antibody therapy of pediatric B-cell lymphoma.	Front Oncol	2013	0.75